Mitomycin
This chemotherapy drug acts like a prodrug that becomes activated inside cells to cross-link DNA strands, preventing cancer cells from dividing. It is used to treat bladder, breast, and other cancers, and can be applied directly into the bladder for bladder cancer treatment.
Molecular Weight
334.3300 g/mol
LogP
-0.40
TPSA
147.00 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D Structure
Cite this structure
Embed this structure
SMILES
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
InChI
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
Molecular Formula
C15H18N4O5
HBD / HBA
3 / 8
Rotatable Bonds
4
Heavy Atoms
24
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
This chemotherapy drug acts like a prodrug that becomes activated inside cells to cross-link DNA strands, preventing cancer cells from dividing. It is used to treat bladder, breast, and other cancers, and can be applied directly into the bladder for bladder cancer treatment.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Mitomycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL105. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5746. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="mitomycin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/mitomycin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/mitomycin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/mitomycin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="mitomycin"></drugfyi-drug>